Loading
IM
IME Stock: price and insider trades · Australia
IME: what insiders have been doing
Every trade that managers of IME disclose to ASX is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 2 filings signed by 2 insiders.
Only sales appear on the open market, 2 sales in all totalling €563k, filed by 2 insiders. One trade stands out by size: a sale of €550k from Douglas Flynn, disclosed on 7 May 2026, or 5.4% of market capitalisation.
Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 2,530 companies) published 3 filings over the same period, against 2 filings here. Looking back to 2026, when coverage begins, insiders filed no purchases and 2 sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€562,557
2 ops. · all time
Who traded when
BuySaleDamian Banks1 sale
Douglas Flynn1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,544 of 24,148 companies
33.2
score / 100
Value19
Quality48
FCF yld-3.8%
Earn yld-16%
EV/EBITDA·
ROE1.2%
Gross mgn100%
Net mgn-9.9%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
A$0.33
Analyst consensus
1 analysts1.00/5
A$0.37Target A$0.37(+14%)A$0.37
Income statement
RevenueA$29M
Gross profitA$29M100% margin
EBITDA-A$452.6k-2% margin
Net income-A$2.9M0.6% margin
Valuation
PER (trailing)32.5x
PER (forward)45.5x
P/Book1.0x
Beta0.81
Balance sheet & cash
Market capA$17.7M
Total debtA$566.3k
Free Cash Flow-A$677.9k
Debt / Equity3%
Profitability & ownership
ROE1.2%
ROA0.5%
% insiders79.1%
% institutions0.0%
Last declaration on 12 June 2026
Declarations2 total
0.13% mcap100.0% of flowShareASXASX:2924-03099766-3A695229
@ A$0.415.35% mcap100.0% of flowShareASXASX:2924-03087835-3A692912
2 of 2 declarations
About IME
IME is a company operating in the health and pharmaceutical sector, listed on the XASX. It focuses on developing innovative solutions to enhance healthcare.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
